List of bibliographic references
Number of relevant bibliographic references: 11.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 7 | Female |
| 7 | Humans |
| 7 | Male |
| 6 | Adult |
| 6 | Middle Aged |
| 4 | Transplantation, Homologous |
| 3 | Adolescent |
| 3 | Aged |
| 3 | Disease-Free Survival |
| 3 | Survival Analysis |
| 3 | Transplantation Conditioning (methods) |
| 2 | Cohort Studies |
| 2 | Hematopoietic Stem Cell Transplantation |
| 2 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (mortality) |
| 2 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (therapy) |
| 2 | Multivariate Analysis |
| 2 | Myeloablative Agonists (therapeutic use) |
| 2 | Prognosis |
| 2 | Recurrence |
| 2 | Siblings |
| 2 | Survival Rate |
| 2 | Transplantation Conditioning |
| 2 | Treatment Outcome |
| 2 | Young Adult |
| 1 | Administration, Intravenous |
| 1 | Administration, Oral |
| 1 | Age |
| 1 | Age Factors |
| 1 | Allografts |
| 1 | Animals |
| 1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 1 | Bone Marrow Transplantation |
| 1 | Bone Marrow Transplantation (adverse effects) |
| 1 | Busulfan (administration & dosage) |
| 1 | Child |
| 1 | Child, Preschool |
| 1 | Chronic Disease |
| 1 | Chronic myelogenous leukemia |
| 1 | Combined Modality Therapy |
| 1 | Cyclophosphamide (administration & dosage) |
| 1 | Demography |
| 1 | Elderly |
| 1 | Follow-Up Studies |
| 1 | Graft vs Host Disease (complications) |
| 1 | Graft vs Host Disease (etiology) |
| 1 | Graft vs Host Disease (mortality) |
| 1 | Graft vs Host Disease (pathology) |
| 1 | Guinea Pigs |
| 1 | HLA Antigens (immunology) |
| 1 | Hematology |
| 1 | Hematopoietic Stem Cell Transplantation (adverse effects) |
| 1 | Hematopoietic Stem Cell Transplantation (methods) |
| 1 | Hematopoietic Stem Cell Transplantation (mortality) |
| 1 | Hematopoietic Stem Cell Transplantation (utilization) |
| 1 | Hematopoietic cell |
| 1 | Histocompatibility |
| 1 | Histocompatibility Testing |
| 1 | Immunosuppressive Agents (therapeutic use) |
| 1 | Infant |
| 1 | Infant, Newborn |
| 1 | International Cooperation |
| 1 | Kaplan-Meier Estimate |
| 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (pathology) |
| 1 | Leukemia, Myeloid, Acute (mortality) |
| 1 | Leukemia, Myeloid, Acute (pathology) |
| 1 | Leukemia, Myeloid, Acute (therapy) |
| 1 | Lymphoma (drug therapy) |
| 1 | Lymphoma (mortality) |
| 1 | Lymphoma (pathology) |
| 1 | Lymphoma (physiopathology) |
| 1 | Lymphoma (therapy) |
| 1 | Lymphoma, Non-Hodgkin (therapy) |
| 1 | Myeloablative Agonists (administration & dosage) |
| 1 | Myelodysplastic Syndromes (mortality) |
| 1 | Myelodysplastic Syndromes (pathology) |
| 1 | Myelodysplastic Syndromes (therapy) |
| 1 | Neoplasm, Residual |
| 1 | Non myeloablative treatment |
| 1 | Odds Ratio |
| 1 | Philadelphia Chromosome |
| 1 | Precursor Cell Lymphoblastic Leukemia-Lymphoma (pathology) |
| 1 | Precursor Cell Lymphoblastic Leukemia-Lymphoma (surgery) |
| 1 | Primary Myelofibrosis (immunology) |
| 1 | Primary Myelofibrosis (mortality) |
| 1 | Primary Myelofibrosis (pathology) |
| 1 | Primary Myelofibrosis (therapy) |
| 1 | Proportional Hazards Models |
| 1 | Protein-Tyrosine Kinases (antagonists & inhibitors) |
| 1 | Remission Induction |
| 1 | Risk |
| 1 | Rituximab (administration & dosage) |
| 1 | Time Factors |
| 1 | Transplantation, Homologous (mortality) |
| 1 | Tyrosine kinase inhibitor |
| 1 | United States |
| 1 | Unrelated Donors (classification) |
| 1 | Whole-Body Irradiation |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "Bipin N. Savani"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "Bipin N. Savani" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Bipin N. Savani
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
